Background: Throughout the COVID-19 pandemic, numerous therapeutic agents have been repurposed and applied empirically and within clinical trials. Prophylactic medications for COVID-19 could have a huge benefit, but studies to date haven’t panned out. Initially many therapeutic medications were used late in …
Background: The COVID-19 Pfizer BNT162b2 vaccine, let’s just call it the COVID-19 Pfizer vaccine (so I don’t have to keep writing BNT162b2) is a novel mRNA vaccine developed to give immunity against the SARS CoV2 virus. It is synthesized mRNA packaged …
Background: SARS-CoV-2 infection has resulted in a high mortality rate, with the majority of deaths resulting from respiratory failure. As waves of the pandemic continue to overwhelm healthcare systems throughout the world, a pragmatic risk stratification tool that would allow …
Background: Despite limited high-quality evidence, many institutions are currently using convalescent plasma therapy (CPT) in the treatment of COVID-19. The majority of the evidence for CPT comes from observational studies lacking placebo arms (US Expanded Access Program). Convalescent plasma therapy …
Background: Throughout the COVID19 pandemic, massive efforts have been invested on the research of effective therapeutics. Much of the research looks at repurposing older treatments (i.e. antimalarial drugs, antiviral agents, interleukin blockers and convalescent plasma therapy). There have been no …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
